Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (28)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by MacGowan, A. P.
Right arrow Articles by Holt, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MacGowan, A. P.
Right arrow Articles by Holt, H. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 43, 345-349
© 1999 The British Society for Antimicrobial Chemotherapy

The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosaassessed by combining antibiotic exposure and bacterial susceptibility

Alasdair P. MacGowan*, Mandy Wootton and H. Alan Holt

Bristol Centre for Antimicrobial Research and Evaluation, Southmead Health Services NHS Trust and University of Bristol, Department of Medical Microbiology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK

Ciprofloxacin has a four-fold greater in-vitro activity than levofloxacin against Pseudomonas aeruginosa, but levofloxacin has a four-fold higher area under the serum concentration-time curve (AUC) for an equivalent dose. It has been proposed that the AUC/MIC ratio is a general predictor of antibacterial efficacy for quinolones. Using an in-vitro kill curve technique, performed in quadruplicate, with nine antibiotic concentrations and three strains of P. aeruginosa with varying quinolone susceptibility, we constructed sigmoidal dose- response curves for AUC0–6.5/MIC and area under the bacterial kill curve (AUBKC) or AUC0–24/MIC and log change in viable count at 24 h ({Delta}24). For levofloxacin the log AUC0–6.5/MIC ratio to produce 50% of the maximal effect was 0.74 ± 0.13 (r2 = 0.9435) for levofloxacin and 0.82 ± 0.06 (r2 = 0.7935) for ciprofloxacin. The log AUC0–24/MIC ratio to produce 50% maximal effect was 1.58 ± 0.13 (r2 = 0.7788) for levofloxacin and 1.37 ± 0.12 (r2 = 0.7207) for ciprofloxacin. An AUC0–24/MIC ratio of 125 produced 85.4% of the maximal response with levofloxacin and 81.5% with ciprofloxacin. These data suggest that levofloxacin and ciprofloxacin have equivalent activity against P. aeruginosa at equivalent AUC/MIC ratios.

* Corresponding author. Tel: +44-117-9595652; Fax: +44-117-9593154.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
D. N. Fish
Bronchoscopic Sampling of Drug Concentrations: Penetration to Tissue Is the Issue
Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1263 - 1265.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. Greko, M. Finn, A. Franklin, and B. Bengtsson
Pharmacokinetic/pharmacodynamic relationship of danofloxacin against Mannheimia haemolytica in a tissue-cage model in calves
J. Antimicrob. Chemother., August 1, 2003; 52(2): 253 - 257.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. P. Lynch III
Hospital-Acquired Pneumonia : Risk Factors, Microbiology, and Treatment
Chest, February 1, 2001; 119 (2009): 373S - 384S.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.